Twin overview
Real-time state of the E3 ligase degradation twin across leukemia and myeloma programs.
Active targets
6
4 ligase families
Median Dmax
86.5%
across validated pairs
Twin drift
12 ms
within tolerance
RAG chunks
9,661
4 grounded corpora
Substrate degradation kinetics
Remaining substrate (%) over 24 h
Cytokine response
Baseline vs post-degrader (pg/mL)
Ligase–substrate matrix
| Pair | Indication | DC50 | Dmax | Ternary | Status |
|---|---|---|---|---|---|
| CRBN-IKZF1 | Multiple Myeloma | 4.2 nM | 96% | 0.91 | in-silico validated |
| VHL-BRD9 | AML | 18.7 nM | 84% | 0.77 | modelled |
| DCAF15-RBM39 | AML | 11.4 nM | 89% | 0.83 | wet-lab queued |
| CRBN-GSPT1 | DLBCL | 2.9 nM | 98% | 0.88 | in-silico validated |
| IAP-BTK | CLL | 43.1 nM | 61% | 0.54 | flagged |
| KEAP1-NRF2 | AML | 26.5 nM | 72% | 0.69 | modelled |
Biomarker signals
- sBCMA clearanceAUC 0.91
Myeloma n=142 · Δ -37%
- MRD flow negativityAUC 0.87
AML n=98 · Δ +24%
- IKZF1 nuclear lossAUC 0.94
Myeloma n=142 · Δ -58%
- ZAP-70 expressionAUC 0.72
CLL n=76 · Δ -11%
- Free light chain ratioAUC 0.83
Myeloma n=142 · Δ -29%
RAG copilot
Grounded in Cereblon neosubstrate atlas · Myeloma cytokine longitudinal set · AML degrader formulation notes · Bio-solvent toxicity registry
research use only